The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | The value of using ctDNA for MRD detection in Hodgkin lymphoma & ongoing work in the field
Sven Borchmann, MD, University Hospital Cologne, Cologne, Germany, comments on the use of circulating tumor DNA (ctDNA) for measurable residual disease (MRD) detection in Hodgkin lymphoma, highlighting its high prognostic value, even at early time points after treatment initiation. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
